ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?"
Episode Synopsis
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
More episodes of the podcast GRACEcast Cancer 101 Audio
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31/07/2014
Management of Rare Kidney Tumors
29/07/2014
NanoString Treatment for Kidney Cancer
24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
What is PD1 and PDL1 in Kidney Cancer?
15/07/2014
In God we trust